Niki BioSolutions, Inc. (NIKI)
Nasdaq · Healthcare · Biotechnology
$4.73+2.79%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $14.7M
- 52-week range
- $4.52 – $25.90
- 52-week change
- −77.99%
- EPS (trailing)
- −$2.90
Fiscal year to Dec 2025
- Net income
- −$1.4M
- Diluted EPS
- −$0.19
From the company’s annual report on SEC EDGAR.
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc.
Headquarters: Princeton, United States · 1 employees · aptorumgroup.com